CYTKCytokinetics, Incorporated
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+14% of shares).
Rangebound, no clear trend. Price is −9% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CYTK is trading
Cytokinetics, Incorporated is +29% over the past year while the S&P 500 is +18%: 11 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −8.5%
vs 200-day average · below trend, but not far
- RSI (14)
- 31
RSI (14) · neutral
- Below its 52-week high
- 26%
Below its 52-week high
Details›
- Last close2026-10-09
- $62.93
- 1 monthS&P 500 +2.7%
- −15%
- 1 yearS&P 500 +18%
- +29%
- 5 yearsS&P 500 +88%
- +90%
- vs 50-day average$71.83
- −12%
- 52-week high
- $84.88
- 52-week low
- $47.83
- Annualised volatility
- 55%
| Year | Return |
|---|---|
| 2026 (year to date) | −0.96% |
| 2025 | +35% |
| 2024 | −44% |
| 2023 | +82% |
| 2022 | +0.53% |
| 2021 | +119% |
| 2020 | +96% |
| 2019 | +68% |
| 2018 | −22% |
| 2017 | −33% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | −1.6% |
| Feb | 10 | 5 of 10 | −1.1% |
| Mar | 10 | 5 of 10 | +1.1% |
| Apr | 10 | 8 of 10 | +9.5% |
| May | 10 | 6 of 10 | +0.39% |
| Jun | 10 | 5 of 10 | +0.30% |
| Jul | 11 | 8 of 11 | +9.4% |
| Aug | 11 | 8 of 11 | +6.2% |
| Sep | 11 | 3 of 11 | −0.44% |
| Oct | 11 | 4 of 11 | −4.1% |
| Nov | 10 | 6 of 10 | +1.1% |
| Dec | 10 | 6 of 10 | +17% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.